帕吉昔單抗

化合物

帕吉昔單抗INN:Pagibaximab)是一種嵌合單克隆抗體,用於預防低出生體重嬰兒葡萄球菌敗血症。截至2010年3月,該藥物尚在進行II/III期臨床試驗[1][2]

帕吉昔單抗
單克隆抗體
種類完整抗體
目標葡萄球菌脂磷壁酸
臨床資料
ATC碼
  • 未分配
識別資訊
CAS號595566-61-3  checkY
ChemSpider
UNII
化學資訊
化學式C6462H9996N1728O2028S54
摩爾質量146,072.36 g·mol−1

參考資料

編輯
  1. ^ Weisman LE, Thackray HM, Garcia-Prats JA, Nesin M, Schneider JH, Fretz J, et al. Phase 1/2 double-blind, placebo-controlled, dose escalation, safety, and pharmacokinetic study of pagibaximab (BSYX-A110), an antistaphylococcal monoclonal antibody for the prevention of staphylococcal bloodstream infections, in very-low-birth-weight neonates. Antimicrobial Agents and Chemotherapy. July 2009, 53 (7): 2879–86. PMC 2704668 . PMID 19380597. doi:10.1128/AAC.01565-08. 
  2. ^ Clinical trial number NCT00646399 for "Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis" at ClinicalTrials.gov